Recent Changes - Search:

Lab

People

Alumni

Downloads

Attach:SBI-color-logo.jpg Δ

edit SideBar

Yunyi Kang, PhD

Contact: ykang@burnham.org

Profile

  • Hometown: Seoul
  • Hobbies: Playing the piano. napping. shopping.
  • Shoes or sandals: anything pretty
  • Music: pop
  • Favorite genre of movies: human drama
  • Television shows: vampire diaries. lost.
  • One item that you cannot live without: internet
  • Favorite quote: Love your neighbors!!

Research Portfolio

  • Education:
Imperial College London, London, UK
Ph.D. Department of Chemical Engineering, Dec 2008
University of Birmingham, Birmingham, London, UK
Master of Science in Biochemical Engineering, Dec 2004
Yonsei University, Seoul, S. Korea
Bachelor of Science in chemical Engineering, Jan 2003
  • Research experience:
Sanford-Burnham medical research institute, San Diego, US
Post-doc, 2010 Mar-Present
UCSD, San Diego, US
Post-doc, Department of Chemistry and Biochemistry, 2009 Mar–2010 Mar
  • Publications:
Y.S. Hwang, Y. Kang, A. Mantalaris. (2007). Directed embryonic stem cell differentiation into osteogenic/chondrogenic lineage in vitro. Biotechnol. Bioprocess Eng. 12(1): 15-21.
Y. Kang, J.M. Nagy, J.M Polak, A. Mantalaris (2009). Proteomic characterization of the conditioned media produced by the visceral endoderm-like cell lines HepG2 and END2: Towards a defined medium for the osteogenic/chondrogenic differentiation of embryonic stem cells. Stem cells and development. 18(1): 77-91.
M. Placzek, J. Cha, Y. Chen, O. Fallata, I. Fauzi, Y.S. Hwang, S. Ismail, Y. Kang, C.Y. Ma, T.M. Mortera, M. Lim, H. Ye, A. Mantalaris. (2008). Stem cell bioprocessing. The journal of the Royal Society, 6(32):209-232.
Y. Kang, A. Mantalaris, J.M. Nagy (2009). Comparison of three commercially available DIGE snalysis software packages using conditioned media sample. Journal of proteome research. 8(2): 1077-1084
J.M.Nagy, Y.Kang, A.G.E. Cass, A. Mantalaris, J.M. Nagy (2008). Finding proteins in cell conditioned media – Novel procedure broadens applications in an effort to control ES cell differentiation. Genetic engineering & biotechnology news. 8:60-61
J Pagkalos, J Cha, Y Kang, M Heliotis, E Tsiridis, A Mantalaris (2010). Simvastatin induces osteogenic differentiation of murine embryonic stem cells. Journal of bone mineral research 25(11): 2470-2478
  • Selected presentations:
Y. Kang, Y.S. Hwang, A. Mantalaris “Characterisation of HepG2 conditioned medium for enhanced mesoderm differentiation of ES cells: Application to skeletal tissue engineering” AiChE -> conference, Nov 2006, San Francisco, CA., US (oral presentation)
Y. Kang , J. Nagy, J.M. Polak, A. Mantalaris “Enhanced osteogenic differentiation using media conditioned by visceral endoderm-like cells and characterization of the conditioned -> -> media” ISSCR annual meeting, June 2007, Cairns, Australia (poster)
Y.Kang, J.M. Polak, A. Mantalaris, J.M. Nagy “2D-DIGE analysis of secreted proteins in two different conditioned medium” July 2007, BSPR-EBI meeting, Cambridge, UK (poster)
J. Nagy, Y. Kang, N. Zhukovsky, A. Mantalaris, A.G.E. Cass “Proteomic characterization of naïve and expended hematopoetic stem cells” Oct 2007, HUPO meeting, Seoul, S. Korea (poster)
Y. Kang, J. Nagy, J.M. Polak, A. Mantalaris “The biological factors identified in HepG2-CM; their stimulatory effects during osteogenic differentiation of mESCs” Dec 2008, TERMIS -> -> meeting, San Diego, CA., US (poster)
J. Pagkalos, Y. Kang, J. Cha, M. Heliotis, E. Tsiridis, A. Mantalaris “The osteo-inductive and osteo-conductive effect of simvastatin in murine embryonic stem cells” June 2010, EFORT -> annual meeting, Madrid, Spain (poster)
  • Research interest:
Our research interest lies on optimizing tumor microenvironment for the personalized therapy. In particular, we are exploiting leukemic cells from childhood acute lymphoblastic leukemia (ALL) patients to devise in-vitro mimicry of patient’ microenvironment that predict in-vivo drug responses. Our long-term aim is the development of the personalized therapy as well as in-vitro testing tools for the patients that don’t respond to the current drug regimes. Also, we are interested in combinatorial drug therapies in various cancer models for the selective treatment.
Edit - History - Print - Recent Changes - Search
Page last modified on September 15, 2011, at 02:55 PM